Joshua Schafer
Net worth: 592 264 $ as of 2026-07-30
Net worth: 592 264 $ as of 2026-07-30
Joshua Schafer currently works as an Advisor at DRI Healthcare and as Chief Commercial Officer & Executive VP at Zevra Therapeutics, Inc. Formerly, Mr. Schafer was Chairman at Pharnext SA from 2023 to 2024, Independent Director at Shuttle Pharmaceuticals Holdings, Inc. from 2019 to 2025, Director at Shuttle Pharmaceuticals, Inc. from 2017 to 2025, Director at Acer Therapeutics, Inc., VP-Oncology, Therapeutic Area & Global Marketing at Astellas Pharma, Inc., and General Manager-Autoimmune & Rare Disease at Mallinckrodt Pharmaceuticals Ltd. from 2020 to 2022.
Education includes undergraduate studies at the University of Notre Dame and graduate studies including an MBA at Northwestern University.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-02-02 | 62,278 ( 0.11% ) | 592 264 $ | 2026-07-30 |
| Companies | Position | Start |
|---|---|---|
| ZEVRA THERAPEUTICS, INC. | Corporate Officer/Principal | 2023-01-08 |
DRI Healthcare
DRI Healthcare Investment ManagersFinance DRI Healthcare invests in royalty interests in leading pharmaceutical and biotechnology companies, research institutions, universities and inventors. | Consultant / Advisor | - |
| Companies | Position | End |
|---|---|---|
Shuttle Pharmaceuticals, Inc.
Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops therapies to improve the outcomes of patients receiving radiation therapy for the treatment of cancers | Director/Board Member | 2025-02-28 |
| SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | Director/Board Member | 2025-02-27 |
| PHARNEXT SCA | Chief Executive Officer | 2022-12-27 |
Mallinckrodt Pharmaceuticals Ltd.
Mallinckrodt Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Corporate Officer/Principal | 2022-11-01 |
| ACER THERAPEUTICS INC. | Director/Board Member | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 10 |
|---|---|
DRI Healthcare
DRI Healthcare Investment ManagersFinance DRI Healthcare invests in royalty interests in leading pharmaceutical and biotechnology companies, research institutions, universities and inventors. | Finance |
University of Notre Dame
University of Notre Dame Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets proprietary prodrugs | Health Technology |
Northwestern University
Northwestern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Astellas Pharma, Inc.
Astellas Pharma, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceuticals and related medical products | Health Technology |
Pharnext SA
Pharnext SA Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops therapies for patients to treat neurodegenerative diseases | Health Technology |
Shuttle Pharmaceuticals, Inc.
Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops therapies to improve the outcomes of patients receiving radiation therapy for the treatment of cancers | Health Technology |
Mallinckrodt Pharmaceuticals Ltd.
Mallinckrodt Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Acer Therapeutics, Inc.
Acer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops and commercializes therapies for serious rare and life-threatening diseases | Health Technology |
Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals products | Health Technology |
Select your edition
All financial news and data tailored to specific country editions